Three major varieties of Jiankangyuan inhalation preparations won bids in the fifth batch of centralized procurement, benefiting more respiratory patients
Published Time:
2021-06-24
On June 23, the fifth round of national drug centralized procurement bidding opened. Three inhaled formulations from HealthGen - Budesonide Suspension for Inhalation (2ml:1mg), Compound Ipratropium Bromide Solution for Inhalation (Shutanlin), and Ipratropium Bromide Solution for Inhalation (Liwu'an) - all won bids!
Among them, in the bidding for Budesonide inhalation (2ml:1mg), a total of 5 pharmaceutical companies participated. After layers of screening, HealthGen's Budesonide Suspension for Inhalation (2ml:1mg) successfully won the bid, ushering in a spring for the development of domestic substitution of inhaled preparations.
Heavyweight Inhaled Products Break Import Monopoly
Since 2013, HealthGen has embarked on a long journey of inhaled formulation research and development. Since 2019, the four inhaled formulations already launched by HealthGen have all obtained high-quality certifications. Among them, the three inhaled formulation varieties that won bids this time each have their own advantages: Budesonide Suspension for Inhalation (Wushu) is the only company in China with both large and small specifications approved, with the children's specification being the first domestically approved imitation; Compound Ipratropium Bromide Solution for Inhalation (Shutanlin) became the first approved inhaled formulation since the country launched the consistency evaluation of generic drugs; Ipratropium Bromide Solution for Inhalation (Liwu'an) was recommended along with the first two products in the "Chronic Obstructive Pulmonary Disease Diagnosis and Treatment Guidelines (2021 revised edition)".
HealthGen's inhaled formulations are mainly used in the asthma and COPD fields. In 2018, the domestic asthma and COPD drug market was approximately 17 billion yuan, with inhaled formulations accounting for 67%. At the same time, the market share of foreign products in this field is over 90%, in an absolutely dominant position. This is because the imitation of inhaled preparations is difficult, and the characteristics of drug-device combinations have extremely high technical requirements, with technical barriers in research and development, approval, and production higher than those of ordinary preparations.
Faced with limited medication choices for domestic patients and difficulties in the research and development and production of inhaled preparations, HealthGen proactively took on the responsibility of "For Health, For Tomorrow," deeply involved in the research and development of inhaled preparations, working with top domestic professional R&D teams and investing massive resources in the research and development of respiratory drugs.
Due to its advantages of minimal drug stimulation, ease of use, good patient compliance, low side effects, and suitability for long-term treatment, inhalation therapy has become the recognized preferred therapy for preventing and treating asthma, chronic obstructive pulmonary disease, and other respiratory diseases.
Currently, HealthGen's existing inhaled preparation varieties cover all categories of asthma and COPD inhaled treatment drugs, breaking the monopoly of multinational companies.
Inhaled Preparation Centralized Procurement Bidding Benefits More Respiratory Patients
Since the approval of multiple inhaled preparation varieties, HealthGen has attached great importance to the production, listing, and centralized procurement of these drugs. This centralized drug procurement is the fifth batch of national centralized drug procurement organized by the state. In terms of implementation, it requires national medical institutions to prioritize the use of centrally procured selected varieties and ensure that the agreed purchase volume is completed. After the selection is determined, the purchase and sales contract is signed and implemented, which will be conducive to the company's rapid opening of the domestic sales market for inhaled preparations, improving market share, promoting the further development of the company's preparation business, and enhancing the company's brand influence.
On the one hand, respiratory diseases are the third largest chronic disease in China, second only to cardiovascular and diabetic diseases, with a large patient population. According to data from the "2019-2025 China Asthma Drug Industry Market Investigation Analysis and Investment Prospect Forecast Report" released by Zhiyan Consulting, the domestic asthma and COPD drug market is approximately 17 billion yuan, with a CAGR of 14% from 2012 to 2018. According to the data, the scale of asthma and COPD medication in 2018 was 4.215 billion yuan. After a fourfold magnification, the actual medication market is approximately 16.9 billion yuan, a year-on-year increase of 9.57%, with the asthma and COPD markets estimated to be 14.7 billion yuan and 2.2 billion yuan, respectively. However, less than 10% of patients in China receive standardized treatment.
On the other hand, the vast majority of the domestic respiratory drug market share has long been occupied by foreign pharmaceutical companies. In 2018, the import share of inhaled formulations for asthma and COPD in Chinese sample hospitals exceeded 93%, while the domestic share was less than 7%.
In the long term, the inclusion of inhaled preparations in national centralized procurement can expand market share and completely break the unbalanced situation of imported drug monopolies. Since its innovative transformation, HealthGen has strived to continuously grow into a research-oriented pharmaceutical company with industry influence under the dual drive of innovation and high-barrier technology platforms.
The trend of domestic substitution has been established, and centralized procurement may become a screening process of "survival of the fittest" on the supply side of the pharmaceutical industry. For products with high industry barriers, once they gain the "favor" of centralized procurement, the future market space and company market value will see a huge increase.
Eight Years of Hard Work Forging Quality with Craftsmanship, Truly Caring for the Health of the Chinese People
Excellent scientific research configuration has become the strong backing of the group. Undeterred by high costs and long timeframes, HealthGen has devoted eight years to honing its skills, and through meticulous manufacturing, it has gradually become one of the few domestic comprehensive pharmaceutical groups with comprehensive layouts and faster progress in high-end inhaled preparations.
The road of research and development is fraught with difficulties and obstacles, with no shortcuts. It requires patience, perseverance, and the ability to withstand setbacks, placing extremely high demands on researchers. From topic selection and research to clinical trials and production, all of this is the result of the unremitting dedication of the research team.
Exceptional quality is revealed in the details. In recent years, HealthGen has focused on the prevention and control of chronic respiratory diseases in China, truly caring for the safety of medication for national patients, selecting topics based on the clinical medication needs of patients, combining imitation and innovation, comprehensively deploying drug formulations, and some products covering adult and pediatric medication, ensuring the output of high-quality, multi-formulation products.
"The Chinese government attaches great importance to this, incorporating the prevention and control of chronic respiratory diseases and other chronic diseases into the national strategy." Li Bin, Vice Minister of the National Health Commission, said that reducing premature mortality from chronic respiratory diseases and other four major chronic diseases is one of the important development goals of the "Healthy China 2030" Planning Outline. HealthGen has always adhered to the pharmaceutical tenet of "For Health, For Tomorrow" and "Making Good Medicines with Care," working together to promote the development of the great health cause.
This time, HealthGen's three inhaled preparation varieties stood out in the national drug centralized procurement, becoming the main force of heavyweight domestic inhaled preparation products, living up to expectations. In the future, HealthGen will continue to innovate, hoping that its meticulous quality will benefit more respiratory patients!